AU2008247439A1 - Use of TP modulators for the treatment of cardiovascular disorders in aspirin sensitive and other populations - Google Patents

Use of TP modulators for the treatment of cardiovascular disorders in aspirin sensitive and other populations Download PDF

Info

Publication number
AU2008247439A1
AU2008247439A1 AU2008247439A AU2008247439A AU2008247439A1 AU 2008247439 A1 AU2008247439 A1 AU 2008247439A1 AU 2008247439 A AU2008247439 A AU 2008247439A AU 2008247439 A AU2008247439 A AU 2008247439A AU 2008247439 A1 AU2008247439 A1 AU 2008247439A1
Authority
AU
Australia
Prior art keywords
aspirin
individual
modulator
adp receptor
sensitive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2008247439A
Other languages
English (en)
Inventor
Patrick Andre
Charles J. Homcy
David R. Phillips
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Portola Pharmaceuticals LLC
Original Assignee
Portola Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Portola Pharmaceuticals LLC filed Critical Portola Pharmaceuticals LLC
Publication of AU2008247439A1 publication Critical patent/AU2008247439A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2008247439A 2007-05-03 2008-05-02 Use of TP modulators for the treatment of cardiovascular disorders in aspirin sensitive and other populations Abandoned AU2008247439A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US91578407P 2007-05-03 2007-05-03
US91578507P 2007-05-03 2007-05-03
US60/915,785 2007-05-03
US60/915,784 2007-05-03
US94728907P 2007-06-29 2007-06-29
US94731607P 2007-06-29 2007-06-29
US60/947,289 2007-06-29
US60/947,316 2007-06-29
PCT/US2008/062565 WO2008137791A1 (en) 2007-05-03 2008-05-02 Use of tp modulators for the treatment of cardiovascular disorders in aspirin sensitive and other populations

Publications (1)

Publication Number Publication Date
AU2008247439A1 true AU2008247439A1 (en) 2008-11-13

Family

ID=39943967

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2008247439A Abandoned AU2008247439A1 (en) 2007-05-03 2008-05-02 Use of TP modulators for the treatment of cardiovascular disorders in aspirin sensitive and other populations
AU2008247441A Abandoned AU2008247441A1 (en) 2007-05-03 2008-05-02 Unit dose formulations and methods of treating and preventing thrombosis with thromboxane receptor antagonists

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2008247441A Abandoned AU2008247441A1 (en) 2007-05-03 2008-05-02 Unit dose formulations and methods of treating and preventing thrombosis with thromboxane receptor antagonists

Country Status (10)

Country Link
US (2) US20090012115A1 (enExample)
EP (2) EP2144999A4 (enExample)
JP (2) JP2010527331A (enExample)
KR (2) KR20100037029A (enExample)
CN (2) CN101711279A (enExample)
AU (2) AU2008247439A1 (enExample)
CA (2) CA2688319A1 (enExample)
IL (2) IL201885A0 (enExample)
MX (2) MX2009011745A (enExample)
WO (2) WO2008137793A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100168137A1 (en) * 2006-12-20 2010-07-01 Johan Raud Combination for use in the treatment of inflammatory disorders
WO2008087371A1 (en) * 2007-01-16 2008-07-24 Cardoz Ab New combination for use in the treatment of inflammatory disorders
KR20130026504A (ko) * 2010-07-14 2013-03-13 큠버랜드 에멀징 테크놀로지스 아이앤씨 트롬복산-a2 수용체 길항제를 이용한 간신증후군 및 간성뇌증의 치료방법
US10016417B2 (en) 2011-11-07 2018-07-10 Diakron Pharmaceuticals, Inc. Extended release formulation of a direct thrombin inhibitor
JP6183459B2 (ja) * 2012-08-06 2017-08-23 Jnc株式会社 合成コラーゲンを用いる二重抗血小板薬／アスピリン応答および反応性試験
US12161632B2 (en) 2014-05-16 2024-12-10 Cumberland Pharmaceuticals Inc. Compositions and methods of treating cardiac fibrosis with ifetroban
JP6273072B2 (ja) * 2014-05-16 2018-01-31 カンバーランド ファーマシューティカルズ，インコーポレーテッド イフェトロバンにより心臓線維症を治療する組成物及び方法
ES2984026T3 (es) * 2015-06-16 2024-10-28 Atxa Therapeutics Ltd Antagonistas del receptor de tromboxano
KR102448406B1 (ko) * 2015-06-30 2022-09-27 큠버랜드 파마슈티컬즈 인코포레이티드 Ａｅｒｄ/천식에서 트롬복산 수용체 길항제
EP3454850B1 (en) 2016-05-11 2023-06-21 Cumberland Pharmaceuticals Inc. Compositions and methods of treating muscular dystrophy with thromboxane-a2 receptor antagonists
AU2021246444A1 (en) * 2020-03-31 2022-10-20 Martin Ogletree Methods and pharmaceutical compositions of thromboxane A2 receptor antagonist for the treatment of COVID-19

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3895115A (en) * 1974-03-01 1975-07-15 Serono Ist Farm Method of inhibiting platelet aggregation
US5071866A (en) * 1989-07-31 1991-12-10 Bristol-Myers Squibb Company Arylpyrazole derivatives as anti-platelet agents
US5506248A (en) * 1993-08-02 1996-04-09 Bristol-Myers Squibb Company Pharmaceutical compositions having good dissolution properties
US5605917A (en) * 1994-12-22 1997-02-25 Bristol-Myers Squibb Company Method of treating dysmenorrhea employing an interphenylene 7-oxabicycloheptyl substituted heterocyclic amide prostaglandin analog
US6509348B1 (en) * 1998-11-03 2003-01-21 Bristol-Myers Squibb Company Combination of an ADP-receptor blocking antiplatelet drug and a thromboxane A2 receptor antagonist and a method for inhibiting thrombus formation employing such combination
JP2005533830A (ja) * 2002-07-09 2005-11-10 ビー．エム．アール．エイ． コーポレイション ベスローテン フェンノートシャップ トロンボキサンａ２受容体アンタゴニストおよびｃｏｘ−２阻害剤の薬剤の組み合わせ
WO2006066008A2 (en) * 2004-12-14 2006-06-22 Portola Pharmaceuticals, Inc. Device and methods for identifying and treating aspirin non-responsive patients
US7381536B2 (en) * 2005-03-01 2008-06-03 Gurbel Paul A Assessment of cardiac health and thrombotic risk in a patient

Also Published As

Publication number Publication date
KR20100037029A (ko) 2010-04-08
MX2009011745A (es) 2010-02-12
CN101711279A (zh) 2010-05-19
IL201886A0 (en) 2010-06-16
CA2688317A1 (en) 2008-11-13
EP2146573A4 (en) 2012-11-21
JP2010527331A (ja) 2010-08-12
US20090012115A1 (en) 2009-01-08
EP2144999A4 (en) 2010-06-16
AU2008247441A1 (en) 2008-11-13
JP2010526104A (ja) 2010-07-29
US20090012136A1 (en) 2009-01-08
CN101686668A (zh) 2010-03-31
KR20100032854A (ko) 2010-03-26
MX2009011744A (es) 2010-02-12
IL201885A0 (en) 2011-08-01
WO2008137793A1 (en) 2008-11-13
EP2144999A1 (en) 2010-01-20
WO2008137791A1 (en) 2008-11-13
CA2688319A1 (en) 2008-11-13
EP2146573A1 (en) 2010-01-27

Similar Documents

Publication Publication Date Title
US20090012115A1 (en) Use of tp modulators for the treatment of cardiovascular disorders in aspirin sensitive and other populations
Cherpokova et al. Resolvin D4 attenuates the severity of pathological thrombosis in mice
Santos-Gallego et al. Overview of aspirin and platelet biology
Rice et al. Optimal medical management of peripheral arterial disease
Altman et al. The antithrombotic profile of aspirin. Aspirin resistance, or simply failure?
US10206891B2 (en) Method of treating cardiovascular events using colchicine concurrently with an antiplatelet agent
Mazaleuskaya et al. Druggable prostanoid pathway
CA2413705A1 (en) Use of meloxicam in combination with an antiplatelet agent for treatment of acute coronary syndrome and related conditions
Lesault et al. Daily administration of the TP receptor antagonist terutroban improved endothelial function in high‐cardiovascular‐risk patients with atherosclerosis
JP2006524203A (ja) トロンビンの過剰形成及び／又はトロンビンレセプターの発現上昇により生じる血栓塞栓性疾病及び疾患の治療及び予防のためのジピリダモール又はモピダモールの使用
JP2011515469A (ja) シクロプロピル−ｎ−｛２−［（１ｓ）−１−（３−エトキシ−４−メトキシフェニル）−２−（メチルスルホニル）エチル］−３−オキソイソインドリン−４−イル｝カルボキサミドを使用した乾癬又は乾癬性関節炎の治療
Gurbel et al. Antiplatelet effect durability of a novel, 24-hour, extended-release prescription formulation of acetylsalicylic acid in patients with type 2 diabetes mellitus
EA029341B1 (ru) Способы предоставления антитромбоцитарной терапии
US9132191B2 (en) Compositions and methods of preventing or ameliorating abnormal thrombus formation and cardiovascular disease
Lorrain et al. Pharmacology of AM803, a novel selective five-lipoxygenase-activating protein (FLAP) inhibitor in rodent models of acute inflammation
Pace-Asciak et al. A new family of thromboxane receptor antagonists with secondary thromboxane synthase inhibition
Chang et al. Endoscopic comparison of the gastroduodenal safety and the effects on arachidonic acid products between meloxicam and piroxicam in the treatment of osteoarthritis
JP2016504994A (ja) 糖尿病患者における心血管リスクの治療
KR20110103428A (ko) 분비성 포스포리파제 Ａ２ （ｓＰＬＡ２） 억제제 또는 ｓＰＬＡ２ 억제제 조합 치료요법을 이용한 주요 유해 심장 사건 및 급성 관상동맥 증후군의 치료
CA3176619A1 (en) Methods and pharmaceutical compositions of thromboxane a2 receptor antagonist for the treatment of covid-19
Tang et al. Additive anti-atherogenic effect of thromboxane receptor antagonism with 12/15lipoxygenase gene disruption in apolipoprotein E-deficient mice
KR20040053884A (ko) 급성 관상동맥증후군 및 관련 상태의 치료를 위한항혈소판제와 병용하는 멜록시캄의 용도
Şahin et al. Analgesic nephropathy
Calatayud et al. Effects of cyclooxygenase-1/cyclooxygenase-2 inhibition on leukocyte/endothelial cell interactions in the rat mesentery
Sica et al. ClinicalChallenges

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period